Amgen Inc. Payments for Restructuring
Amgen Inc. (AMGN) reported Payments for Restructuring of $31.00 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-13.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2018-02-13
- Amgen Inc. payments for restructuring for the quarter ending 2015-12-31 was $19.00M.
- Amgen Inc. payments for restructuring for the quarter ending 2015-09-30 was $59.00M, a 5800.00% increase year-over-year.
- Amgen Inc. payments for restructuring for the quarter ending 2015-06-30 was $71.00M.
- Amgen Inc. payments for restructuring for the quarter ending 2015-03-31 was $109.00M.
- Amgen Inc. payments for restructuring for fiscal 2017 was $31.00M, a 73.50% decline from fiscal 2016.
- Amgen Inc. payments for restructuring for fiscal 2016 was $117.00M, a 54.65% decline from fiscal 2015.
- Amgen Inc. payments for restructuring for fiscal 2015 was $258.00M, a 82.98% increase from fiscal 2014.
- Amgen Inc. payments for restructuring for fiscal 2014 was $141.00M.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2017-12-31 | $31.00M 10-K · filed 2018-02-13 | |||
| 2016-12-31 | $117.00M 10-K · filed 2018-02-13 | |||
| 2015-12-31 | $19.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $78.00M derived: sum of 2 quarters · filed 2018-02-13 | $149.00M derived: sum of 3 quarters · filed 2018-02-13 | $258.00M 10-K · filed 2018-02-13 |
| 2015-09-30 | $59.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-02 | $130.00M derived: sum of 2 quarters · filed 2015-11-02 | $239.00M 10-Q · filed 2015-11-02 | |
| 2015-06-30 | $71.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $180.00M 10-Q · filed 2015-08-05 | ||
| 2015-03-31 | $109.00M 10-Q · filed 2015-04-27 | |||
| 2014-12-31 | $141.00M 10-K · filed 2018-02-13 | |||
| 2014-09-30 | $1.00M 10-Q · filed 2014-10-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |